Hugo Laviada-Molina

Hugo Laviada-Molina

Auto-generated profile, based on publicly available information

Hugo Laviada-Molina

Universidad Marista de Mérida

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2020 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
HLHugo Laviada‐Molina
Hugo Laviada‐Molina
FMFernanda Molina‐Segui
Fernanda Molina‐Segui
GPGiordano Pérez‐Gaxiola
Giordano Pérez‐Gaxiola
CCCarlos Cuello‐García
Carlos Cuello‐García
RARuy David Arjona-Villicaña
Ruy David Arjona-Villicaña
Raigam Jafet Martinez Martinez-PortillaRaigam Jafet Martinez Martinez-Portilla
Raigam Jafet Martinez Martinez-Portilla

25 June 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
Lluis Serra-MajemLluis Serra-Majem
Lluis Serra-Majem
ARAntónio Raposo
António Raposo
JAJavier Aranceta
Javier Aranceta
Gregorio Varela-MoreirasGregorio Varela-Moreiras
Gregorio Varela-Moreiras
CLCaomhan Logue
Caomhan Logue
SSSérgio Cunha Velho de Sousa
Sérgio Cunha Velho de Sousa
International scientific experts in food, nutrition, dietetics, endocrinology, physical activity, paediatrics, nursing, toxicology and public health met in Lisbon on 2–4 July 2017 to develop a Consensus on the use of low- and no-calorie sweeteners (LNCS) as substitutes for sugars and other caloric sweeteners. LNCS are food additives that are broadly used as sugar substitutes to sweeten foods and beverages with the addition of fewer or no calories. They are also used in medicines, health-care products, such as toothpaste, and food supplements. The goal of this Consensus was to provide a useful, evidence-based, point of reference to assist in efforts to reduce free sugars consumption in line with current international public health recommendations. Participating experts in the Lisbon Consensus analysed and evaluated the evidence in relation to the role of LNCS in food safety, their regulation and the nutritional and dietary aspects of their use in foods and beverages. The conclusions of this Consensus were: (1) LNCS are some of the most extensively evaluated dietary constituents, and their safety has been reviewed and confirmed by regulatory bodies globally including the World Health Organisation, the US Food and Drug Administration and the European Food Safety Authority; (2) Consumer education, which is based on the most robust scientific evidence and regulatory processes, on the use of products containing LNCS should be strengthened in a comprehensive and objective way; (3) The use of LNCS in weight reduction programmes that involve replacing caloric sweeteners with LNCS in the context of structured diet plans may favour sustainable weight reduction. Furthermore, their use in diabetes management programmes may contribute to a better glycaemic control in patients, albeit with modest results. LNCS also provide dental health benefits when used in place of free sugars; (4) It is proposed that foods and beverages with LNCS could be included in dietary guidelines as alternative options to products sweetened with free sugars; (5) Continued education of health professionals is required, since they are a key source of information on issues related to food and health for both the general population and patients. With this in mind, the publication of position statements and consensus documents in the academic literature are extremely desirable.

1 April 2006 in Emerging Infectious Diseases
Verified
Journal Article
Open access
JZJorge E. Zavala-Castro
Jorge E. Zavala-Castro
JZJorge E. Zavala-Velázquez
Jorge E. Zavala-Velázquez
DWDavid H. Walker
David H. Walker
EAEdgar E. Ruiz Arcila
Edgar E. Ruiz Arcila
HLHugo Laviada-Molina
Hugo Laviada-Molina
KDKarla R. Dzul-Rosado
Karla R. Dzul-Rosado
The first fatal Rickettsia rickettsii infection was diagnosed in the southwest of Mexico. The patient had fever, erythematous rash, abdominal pain, and severe central nervous system involvement with convulsive crisis. The diagnosis of R. rickettsii infection was established by immunohistochemistry and specific polymerase chain reaction.

1 December 2002 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
PDF file
IVIgnacio Vado-Solís
Ignacio Vado-Solís
María Fidelia Cárdenas-MarrufoMaría Fidelia Cárdenas-Marrufo
María Fidelia Cárdenas-Marrufo
BJBertha Jiménez-Delgadillo
Bertha Jiménez-Delgadillo
AAAlejandro Alzina-López
Alejandro Alzina-López
HLHugo Laviada-Molina
Hugo Laviada-Molina
JZJorge E. Zavala-Velázquez
Jorge E. Zavala-Velázquez
A leptospirosis clinical-epidemiological study was made in humans and reservoirs in the state of Yucatán, México. Interviews and serological analyses were made on 400 persons from an open population, 439 probable cases of leptospirosis and 1060 animal reservoirs (cows, pigs, dogs, rats and opossums). IgM Leptospira DipstickTM and Microscopic Agglutination Test (MAT) was used to detect human antibodies to leptospiras and serovar respectively. Leptospirosis incidence in humans was 2.2/100,000 inhab. in 1998, 0.7/100,000 in 1999 and 0.9/100,000 in 2000. Overall seroprevalence was 14.2%, relatively unchanged from seroprevalences observed 20 years ago. Highest seropositivity was found in people over 56 years of age, predominating males over females. Predominant serovars in the open population were tarassovi, hardjo, pomona and panama. Leptospirosis cases were most frequent in rural areas, and the anicteric course predominated over the icteric. The panama, icterohaemorrhagiae and pomona serovars predominated in both anicteric and icteric courses. Dogs, pigs and rodents had the highest seropositivity among the reservoirs. Contact with rodents and natural water sources were significant factors (p £ 0.05). Human cases (74%) occurred during the rainy season. It is concluded that leptospirosis is still a serious illness with important clinical and epidemiological implications in the state of Yucatán, Mexico.

2 October 2024 in Current Obesity Reports
Verified
Journal Article
Open access
PDF file
ECEmma A. Chávez-Manzanera
Emma A. Chávez-Manzanera
JVJuan M. Vera-Zertuche
Juan M. Vera-Zertuche
MKMartha Kaufer-Horwitz
Martha Kaufer-Horwitz
VVVerónica Vázquez-Velázquez
Verónica Vázquez-Velázquez
JFJosé R. Flores-Lázaro
José R. Flores-Lázaro
XSXimena Ramos Salas
Ximena Ramos Salas
Purpose To develop Mexico’s first methodologically rigorous clinical practice guideline for the management of adult overweight and obesity. The target audiences are interdisciplinary healthcare professionals across healthcare systems who are the first point of contact for patients with obesity in Mexico, patients, and health system decision makers. Recent Findings A review of recent international obesity clinical practice guidelines and an expert consensus process identified: i) common recommendations appropriate for implementation in Mexico and ii) knowledge gaps requiring the formulation of new recommendations. In all, 20 new recommendations and 20 good practice statements were developed using the GRADE Evidence-to-Decision Framework and expert consensus. Summary Overweight and obesity negatively impact the health and well-being of individuals and populations in Mexico. This guideline aims to establish a new evidence-based, patient-centered, non-stigmatizing, and practical treatment and management framework, based on the fundamental principles of chronic disease prevention and management.

1 April 2006 in Archives of Medical Research
Verified
Journal Article
Closed access
JZJorge Zavala-Velazquez
Jorge Zavala-Velazquez
HLHugo Laviada-Molina
Hugo Laviada-Molina
JZJorge Zavala-Castro
Jorge Zavala-Castro
CPCarlos Perez-Osorio
Carlos Perez-Osorio
GBGerardo Becerra-Carmona
Gerardo Becerra-Carmona
DWDavid H. Walker
David H. Walker